Coronavirus vaccine developer CureVac shares surge in U.S. debut

10Views

August 14, 2020

Shares of German biotechnology firm CureVac BV nearly tripled in their Nasdaq debut on Friday, marking the first stock market debut of a company developing a potential vaccine to combat the novel coronavirus.

The stock opened at $44 per share, up from the initial public offering (IPO) price of $16 per share.

CureVac, backed by Microsoft Corp founder and billionaire Bill Gates, sold 13.33 million shares at $16 apiece, the top end of its indicated price range of between $14 and $16 per share.

The company, which started an early-stage coronavirus trial in healthy volunteers in June with results expected in the final quarter of 2020, raised $213.3 million in the IPO.

Proceeds from the IPO would be used to fund its COVID-19 vaccine program and manufacturing capabilities, CureVac said in a regulatory filing.

The company is working to expand its capacity with a new manufacturing facility in Germany that will be capable of producing billions of vaccine doses.

CureVac is in talks with large drugmakers about a partnership to help market and distribute its prospective vaccine, its chief executive officer told German newspaper Sueddeutsche Zeitung on Friday.

The company is researching how to use messenger RNA to fight cancer, rabies and other illnesses, including the coronavirus.

In June, the German government took a 23% stake in CureVac for about $343 million. In July, GlaxoSmithKline and the Qatar Investment Authority also bought a stake in the company.

Tuebingen-based CureVac secured a 75-million-euro loan from the European Investment Bank last month.

SAP SE co-founder Dietmar Hopp owns a controlling stake in CureVac and is expected to hold a little less than 50% after the listing, according to a company filing.

Also Watch

Zoom COO Aparna Bawa On Zoom’s Success Story In India | Brass Tacks | CNN News118

Bank of America, Jefferies, and Credit Suisse are lead underwriters for the IPO.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Array
(
[videos] => Array
(
[0] => Array
(
[id] => 5f36c4f1046bae25c91dbb2b
[youtube_id] => uJUojvJ6fkY
Coronavirus vaccine developer CureVac shares surge in U.S. debut => Zoom COO Aparna Bawa On Zoom’s Success Story In India | Brass Tacks | CNN News118
)

[1] => Array
(
[id] => 5f36c34da07a3a25bbc1d171
[youtube_id] => 6nNa4A_SPxg
Coronavirus vaccine developer CureVac shares surge in U.S. debut => Chinese Hawala Crackdown Merely Tip Of The Iceberg? | Brass Tacks | CNN News18
)

)

[query] => https://pubstack.nw18.com/pubsync/v1/api/videos/recommended?source=n18english&channels=5d95e6c378c2f2492e2148a2,5d95e6c278c2f2492e214884,5d96f74de3f5f312274ca307&categories=5d95e6d7340a9e4981b2e10a&publish_min=2020-08-11T22:42:02.000Z&publish_max=2020-08-14T22:42:02.000Z&sort_by=date-relevance&order_by=0&limit=2
)

Coronavirus vaccine developer CureVac shares surge in U.S. debut

Also Watch

Speak Your Mind

LEAVE A REPLY Cancel reply

Get in Touch

Recommend for You

Oh hi there It’s nice to meet you.

Subscribe and receive our weekly newsletter packed with awesome articles that really matters to you!

You might also like

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

About Us

Follow Us

Support Us & Be a Patreon

Add QNewsHub to your Homescreen!

Oh hi there
It’s nice to meet you.